Non-upper aerodigestive tract NK/T- cell lymphoma: an analysis of clinical features and survival from a single center in China.
- Author:
Ningjing LIN
1
;
Yuqin SONG
1
;
Wen ZHENG
1
;
Meifeng TU
1
;
Yan XIE
1
;
Xiaopei WANG
1
;
Zhitao YING
1
;
Lingyan PING
1
;
Chen ZHANG
1
;
Weiping LIU
1
;
Jun ZHU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine; Young Adult
- From: Chinese Journal of Hematology 2015;36(1):29-33
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze clinical features and outcomes of non-upper aerodigestive tract NK/T-cell lymphoma (NUAT-NKTCL).
METHODSClinical data of 44 patients with NUAT-NKTCL diagnosed at Peking University Cancer Hospital between 1999 and 2013 were retrospectively analyzed.
RESULTSOf the 44 patients, there were 31 males and 13 females with a median age of 39 years (range, 15 to 82 years). 27 patients (61.4%) were stage III/IV, 28(63.6%) with B symptoms, 12(27.3%) ECOG ≥ 2, 18 (40.9%) IPI score ≥ 3, and 48.8% patients had elevated serum lactate dehydrogenase. The common primary sites were skin (21/44, 47.2%) and intestinal tract (11/44, 25.0%). All the 44 patients received systemic chemotherapy. After a median follow-up of 13.5 months (range, 0.3-121.0 months), 32 patients died, and the median overall survival (OS) was 16 months with 1-year OS rate as 54.1%. CR rate of the 26 patients received CHOP or CHOPE regimens as the first line chemotherapy was 19.2% (5/26). Then L-asparaginase (L-ASP)- based regimens were used for salvage treatment, with CR rate of 47.7% and the median OS of 13 months. CR rate of the other 18 patients received L-ASP-based regimens in the firstline therapy was 55.6% (10/18) with the median OS of 16 months. Using L-ASP in firstline treatment obviously improved CR rate (P=0.015), but did not affect OS (P=0.774).
CONCLUSIONAlthough L-ASP improved the efficacy of NUAT-NKTCL, but the prognosis remained dismal. Thus, more effective treatment strategies are required for NUAT-NKTCL.
